Our history
LFB BIOMANUFACTURING: Sizeable player with regular capacity add-ns and strategic certifications
1997 - 2007 : Inception of MAbgène
1997 : Creation of MAbgène
2001 : ISO 9001 certification
2003 : 1st GMP facilities
2006 : ANSM Audit (API statut )
2007 - 2010 : Integration into the LFB Group
2007: Acquisition of MAbgène by LFB
2008: Implementation of single-use technology
2009: Implementation of 1,000L disposable bioreactor technology
2010: Implementation of a GMP area for buffer and media preparation
2012 - 2017 : Site expansion and production development
2012: MAbgène becomes LFB BIOMANUFACTURING
2014 – 2016: New GMP facilities (UP2):
- GMP manufacturing area increase from sqm 150 to 750 sqm
- Integrated upstream and downstream capacities
- Single-use equipment
- € 14 M Capex over the period
2017 - 2022 : Internationalisation of LFB BIOMANUFACTURING
2017: FDA pre-licensing approval inspection
2020:
- Production of first commercial batches for the recombinant activated Factor VII
- FDA approval
2022 - 2030 : ESCAPE30 New development Strategy
2022 – 2025: Flawless execution
- Strategic site investments: LFB BIOMANUFACTURING will double its bioproduction capacity
- Accelerated business development